Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04191187
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:50.992454+00:00
Published At
2025-03-07T00:00:00+00:00
Record Updated At
2025-12-11
Results Posted At
2025-03-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia", "Myeloproliferative Neoplasm", "Relapsed Large Cell Lymphoma", "Mantle Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Relapsed Small Lymphocytic Lymphoma", "Relapsed Marginal B-cell Lymphoma", "Relapsed Follicular Lymphoma", "Lymphoplasmacytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-11"
protocolSection.identificationModule.nctId
"NCT04191187"
protocolSection.identificationModule.officialTitle
"Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-03-07"

Study condition terms

  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Biphenotypic Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Undifferentiated Leukemia (protocolSection.conditionsModule.conditions)
  • Prolymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Relapsed Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Relapsed T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Relapsed Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Relapsed Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Relapsed Marginal B-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Relapsed Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.